Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The community screening programme charts an effective, affordable framework for TB control in the Canadian province of ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Oak Hill Bio and Chiesi have enrolled the first European patient in a Phase IIb study for OHB-607, to prevent BPD in infants.

The Phase III trial will investigate the Steriwave light-activated antimicrobial technology to reduce healthcare-associated infections. Image credit: Nicoleta Ionescu / Shutterstock. Ondine Biomedical ...

Allurion expects to complete the US approval filling next year, with data from its pivotal trial. Image credit: ichefboy / Shutterstock. Allurion Technologies has presented data from two studies ...

The world of clinical trials is undergoing a rapid change. Today, the rise of decentralized clinical trials (DCTs) and hybrid ...

Sutro Biopharma has begun the REFRαME-P1 trial of Luvelta to treat paediatric patients with a type of acute myeloid leukaemia (AML).

The R3 Vascular investigational device exemption will be used to launch a pivotal trial of its treatment for peripheral arterial disease.

Endevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate into clinical trials.

Memo Therapeutics has completed patient enrolment for its Phase II trial of potravitug, for BK viremia (BKV) in kidney ...